Located in North Carolina, Tranzyme is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. Today, Tranzyme took a major step towards prominence with the announcement they have been ranked as the 54th fastest growing company in North American on Deloitte’s 2011 Technology Fast 500.
Leading the way at Tranzyme Pharma is Vipin Garg whom serves as the company’s President and CEO. In reference to this honor, Garg was quoted as saying, “We are very pleased to be recognized by Deloitte as one of the fastest growing companies in North America. The licensing fees we received from our strategic partners, Norgine B.V., and Bristol-Meyers Squibb reflect the growth of our topline and support our development activities.”
Eric Openshaw, whom serves as the vice chairman and U.S. technology, media and telecommunications leader of Deloitte LLP, stated, “Tranzyme Pharma, like all 2011 Technology Fast 500™ companies, has excelled in fostering innovation and channeling it into spectacular growth against the backdrop of one of the most challenging economies in history. Deloitte recognizes Tranzyme Pharma for its remarkable accomplishment.”
Currently, Tranzyme is trading in the $2.98 range. With this prestigious honor and an array of technology within their corporate pipeline, Tranzyme Pharma is a company on the rise.
To learn more about the company as a whole, visit their corporate website at: www.tranzyme.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
